Answers are grounded in this paper and cite their sources.
Twelve months of ecopipam dosing was well tolerated during this study and no new adverse events were detected. Compared to baseline, significantly reduced TS symptom severity and improved QOL were observed in children and adolescents.
No takes yet. Share an insight, caveat, or question.
Gilbert et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: